295 related articles for article (PubMed ID: 22204649)
1. Transdermal delivery of alprazolam from a monolithic patch: formulation based on in vitro characterization.
Soler LI; Boix A; Lauroba J; Colom H; Domenech J
Drug Dev Ind Pharm; 2012 Oct; 38(10):1171-8. PubMed ID: 22204649
[TBL] [Abstract][Full Text] [Related]
2. Effect of permeation enhancers on dynamic mechanical properties of acrylate pressure sensitive adhesives.
Khire A; Vavia P
Int J Pharm; 2013 Dec; 458(1):141-7. PubMed ID: 24120455
[TBL] [Abstract][Full Text] [Related]
3. Formulation and in vitro/in vivo evaluation of levodopa transdermal delivery systems.
Lee KE; Choi YJ; Oh BR; Chun IK; Gwak HS
Int J Pharm; 2013 Nov; 456(2):432-6. PubMed ID: 24008082
[TBL] [Abstract][Full Text] [Related]
4. Silicone adhesive, a better matrix for tolterodine patches-a research based on in vitro/in vivo studies.
Liu J; Wang Z; Liu C; Xi H; Li C; Chen Y; Sun L; Mu L; Fang L
Drug Dev Ind Pharm; 2012 Aug; 38(8):1008-14. PubMed ID: 22126709
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of skin permeation of bufalin by limonene via reservoir type transdermal patch: formulation design and biopharmaceutical evaluation.
Yang Z; Teng Y; Wang H; Hou H
Int J Pharm; 2013 Apr; 447(1-2):231-40. PubMed ID: 23467076
[TBL] [Abstract][Full Text] [Related]
6. Effects of pressure sensitive adhesives and chemical permeation enhancers on the permeability of fentanyl through excised rat skin.
Mehdizadeh A; Ghahremani MH; Rouini MR; Toliyat T
Acta Pharm; 2006 Jun; 56(2):219-29. PubMed ID: 16613727
[TBL] [Abstract][Full Text] [Related]
7. Development of transdermal therapeutic formulation of CNS5161, a novel NMDA receptor antagonist, by utilizing pressure-sensitive adhesives II: improved transdermal absorption and evaluation of efficacy and safety.
Naruse M; Ogawara K; Kimura T; Konishi R; Higaki K
Eur J Pharm Sci; 2014 Feb; 52():86-94. PubMed ID: 24215737
[TBL] [Abstract][Full Text] [Related]
8. Drug in Adhesive Patch of Zolmitriptan: Formulation and In vitro /In vivo Correlation.
Liu C; Fang L
AAPS PharmSciTech; 2015 Dec; 16(6):1245-53. PubMed ID: 25771739
[TBL] [Abstract][Full Text] [Related]
9. Development of a drug-in-adhesive patch combining ion pair and chemical enhancer strategy for transdermal delivery of zaltoprofen: pharmacokinetic, pharmacodynamic and in vitro/in vivo correlation evaluation.
Cui H; Quan P; Zhou Z; Fang L
Drug Deliv; 2016 Nov; 23(9):3461-3470. PubMed ID: 27257038
[TBL] [Abstract][Full Text] [Related]
10. Transdermal patches for site-specific delivery of anastrozole: In vitro and local tissue disposition evaluation.
Xi H; Yang Y; Zhao D; Fang L; Sun L; Mu L; Liu J; Zhao N; Zhao Y; Zheng N; He Z
Int J Pharm; 2010 May; 391(1-2):73-8. PubMed ID: 20170718
[TBL] [Abstract][Full Text] [Related]
11. In vitro transdermal delivery of caffeine, theobromine, theophylline and catechin from extract of Guarana, Paullinia Cupana.
Heard CM; Johnson S; Moss G; Thomas CP
Int J Pharm; 2006 Jul; 317(1):26-31. PubMed ID: 16600539
[TBL] [Abstract][Full Text] [Related]
12. Formulation and evaluation of ubidecarenone transdermal delivery systems.
Jung SY; Kang EY; Choi YJ; Chun IK; Lee BK; Gwak HS
Drug Dev Ind Pharm; 2009 Sep; 35(9):1029-34. PubMed ID: 19365779
[TBL] [Abstract][Full Text] [Related]
13. Adhesive properties: a critical issue in transdermal patch development.
Cilurzo F; Gennari CG; Minghetti P
Expert Opin Drug Deliv; 2012 Jan; 9(1):33-45. PubMed ID: 22171789
[TBL] [Abstract][Full Text] [Related]
14. Formulation study of a patch containing propranolol by design of experiments.
Cilurzo F; Minghetti P; Gennari CG; Casiraghi A; Selmin F; Montanari L
Drug Dev Ind Pharm; 2014 Jan; 40(1):17-22. PubMed ID: 23301830
[TBL] [Abstract][Full Text] [Related]
15. Development and evaluation of a drug-in-adhesive transdermal delivery system for delivery of olanzapine.
Vora D; Banga AK
Expert Opin Drug Deliv; 2022 Nov; 19(11):1539-1548. PubMed ID: 36242524
[TBL] [Abstract][Full Text] [Related]
16. Influence of formulation variables in transdermal drug delivery system containing zolmitriptan.
Subedi RK; Ryoo JP; Moon C; Choi HK
Int J Pharm; 2011 Oct; 419(1-2):209-14. PubMed ID: 21843607
[TBL] [Abstract][Full Text] [Related]
17. Drug recrystallization in drug-in-adhesive transdermal delivery system: A case study of deteriorating the mechanical and rheological characteristics of testosterone TDS.
Mohamed LA; Kamal N; Elfakhri KH; Willett D; Wokovich A; Strasinger C; Cruz CN; Raney SG; Ashraf M; Zidan AS
Int J Pharm; 2020 Mar; 578():119132. PubMed ID: 32057892
[TBL] [Abstract][Full Text] [Related]
18. Permeation enhancers compatible with transdermal drug delivery systems. Part I: selection and formulation considerations.
Pfister WR; Hsieh DS
Med Device Technol; 1990; 1(5):48-55. PubMed ID: 10171148
[TBL] [Abstract][Full Text] [Related]
19. Development of matrix patches for transdermal delivery of a highly lipophilic antiestrogen.
Funke AP; Günther C; Müller RH; Lipp R
Drug Dev Ind Pharm; 2003 Aug; 29(7):785-93. PubMed ID: 12906336
[TBL] [Abstract][Full Text] [Related]
20. Double-layer weekly sustained release transdermal patch containing gestodene and ethinylestradiol.
Gao Y; Liang J; Liu J; Xiao Y
Int J Pharm; 2009 Jul; 377(1-2):128-34. PubMed ID: 19463930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
